TITLE

Lamivudine

AUTHOR(S)
Jarvis, Blair; Faulds, Diana
PUB. DATE
July 1999
SOURCE
Drugs;Jul1999, Vol. 58 Issue 1, p101
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Lamivudine is a deoxycytidine analogue that is active against hepatitis B virus (HBV). In patients with chronic hepatitis B, lamivudine profoundly suppresses HBV replication. Clinically significant improvements in liver histology and biochemical parameters were obtained with lamivudine in double-blind, randomised, trials in hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B and compensated liver disease. After 52 weeks of treatment, relative to placebo (≤25%), significantly more Chinese (56%) or Western patients (52%) treated with lamivudine 100 mg/day had reductions of ≥ 2 or more points in Knodell necro-inflammatory scores. Moreover, significantly fewer lamivudine 100 mg/day than placebo recipients had progressive fibrosis in liver biopsies (≤5 vs ≥ 15%) and fewer lamivudine- than placebo-treated patients progressed to cirrhosis (1.8 vs 7.1%). More lamivudine 100 mg/day than placebo recipients acquired antibodies to HBeAg after 52 weeks (16 vs 4% in Chinese patients and 17 vs 6% in Western patients). ALT levels normalised in significantly more lamivudine than placebo recipients enrolled in these trials. In HBeAg-negative, HBV DNA positive patients with compensated liver disease enrolled in a double-blind, randomised study, HBV DNA levels were suppressed to below the limit of detection (< 2.5 pg/ml) and ALT levels normalised in 63% and 6% of patients treated with lamivudine 100 mg/day or placebo for 24 weeks. Clinically significant improvements in liver histology were obtained in 60% of patients treated with lamivudine for 52 weeks in this study. Lamivudine 100 mg/day for 52 weeks produced similar or significantly greater improvements in liver histology and ALT levels than 24 weeks' treatment with lamivudine plus interferon-α. In liver transplant candidates with chronic hepatitis B and end-stage liver disease, lamivudine 100 mg/day alone, or in combination with hepatitis B immune globulin, generally suppressed HBV...
ACCESSION #
9523859

 

Related Articles

  • Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen—Negative Chronic Hepatitis B. Hadziyannis, Stephanos J.; Tassopoulos, Nicolaos C.; Heathcote, E. Jenny; Chang, Ting-Tsung; Kitis, George; Rizzetto, Mario; Marcellin, Patrick; Lim, Seng Gee; Goodman, Zachary; Wulfsohn, Michael S.; Xiong, Shelly; Fry, John; Brosgart, Carol L. // New England Journal of Medicine;2/27/2003, Vol. 348 Issue 9, p800 

    Background: Adefovir dipivoxil, a nucleotide analogue, demonstrated clinically significant antiviral activity in patients with chronic hepatitis B in phase 1 and 2 clinical trials. Methods: We randomly assigned 185 patients with chronic hepatitis B who were negative for hepatitis B e antigen...

  • Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen—Positive Chronic Hepatitis B. Marcellin, Patrick; Chang, Ting-Tsung; Lim, Seng Gee; Tong, Myron J.; Sievert, William; Shiffman, Mitchell L.; Jeffers, Lennox; Goodman, Zachary; Wulfsohn, Michael S.; Xiong, Shelly; Fry, John; Brosgart, Carol L. // New England Journal of Medicine;2/27/2003, Vol. 348 Issue 9, p808 

    Background: In preclinical and phase 2 studies, adefovir dipivoxil demonstrated potent activity against hepatitis B virus (HBV), including lamivudine-resistant strains. Methods: We randomly assigned 515 patients with chronic hepatitis B who were positive for hepatitis B e antigen (HBeAg) to...

  • Antiviral treatment in chronic infection with hepatitis B virus. Alexander, Graeme; William, Roger // British Medical Journal (Clinical Research Edition);4/5/1986, Vol. 292 Issue 6525, p915 

    Investigates the use of antiviral agents in the treatment of chronic infection with Hepatitis B virus in Great Britain. Risk of patient with hepatitis B to develop chronic liver disease; Relationship between active viral replication and histological activity; Detection by highly sensitive...

  • Integrity of c-Raf-1/MEK signal transduction cascade is essential for hepatitis B virus gene expression. Stockl, Lars; Berting, Andreas; Malkowski, Beate; Foerste, Ramona; Hofschneider, Peter Hans; Hildt, Eberhard // Oncogene;5/1/2003, Vol. 22 Issue 17, p2604 

    The genome of hepatitis B virus (HBV) encodes two transcriptional activators: the HBx protein and the PreS2-activator large surface protein (LHBs). Both proteins trigger activation of c-Raf-1/MEK kinase cascade. In case of HBx this can be mediated by a PKC-independent and Ras-dependent...

  • 2009 - Review: Evidence is insufficient to evaluate effectiveness of antiviral therapies for chronic hepatitis B. Reichen, J. // ACP Journal Club;5/19/2009, Vol. 150 Issue 5, p4 

    The article discusses studies which were conducted to find out whether antiviral therapy is effective in patients with chronic hepatitis B infection. Meta-analysis showed that entecavir and lamivudine did not differ for death or hepatic decompensation. Individual RCTs showed that antiviral drugs...

  • Mild-to-Moderate Elevation of Alanine Aminotransferase Increases Liver Stiffness Measurement by Transient Elastography in Patients With Chronic Hepatitis B. James Fung; Ching-Lung Lai; Charles Cheng; Ringo Wu; Danny Ka-Ho Wong; Man-Fung Yuen // American Journal of Gastroenterology;Mar2011, Vol. 106 Issue 3, p492 

    OBJECTIVES:Liver stiffness measurement has been shown to be increased in severe acute flares of hepatitis. Whether lesser degree of hepatitis can also increase liver stiffness is not known. The present study aimed to investigate the effect of mild-to-moderate elevations of alanine...

  • Clinical course of patients with chronic hepatitis B with viral breakthrough during long-term lamivudine treatment. Ide, Tatsuya; Kumashiro, Ryukichi; Kuwahara, Reiichiro; Koga, Hiroyuki; Koga, Yuriko; Hino, Teruko; Tanaka, Kazuo; Hisamochi, Akiko; Ogata, Kei; Sata, Michio // Journal of Gastroenterology;Jun2005, Vol. 40 Issue 6, p625 

    Background. We evaluated the clinical course of patients with chronic hepatitis B who showed viral breakthrough during long-term lamivudine therapy. Methods. We initially studied 141 patients treated with lamivudine for 1 year or more, and 49 patients who showed viral breakthrough were the...

  • LONG-TERM EFFECT OF ALPHA-INTERFERON THERAPY IN CHRONIC HEPATITIS B. Sampliner, Richard E.; Johnson, David A.; Cattau Jr., Edward L. // American Journal of Gastroenterology;Dec1991, Vol. 86 Issue 12, p1838 

    Studies the long-term effect of alpha-interferon therapy in chronic hepatitis B. Response of the patients to the therapy; Barrier to the wider application of antiviral therapy; Predisposing reasons for relapse in patients.

  • Management of Hepatitis B Virus before and after Renal Transplant. Kulik, Laura; Mohanty, Smruti R. // Kidney;Jul/Aug2003, Vol. 12 Issue 4, p151 

    It has been well documented that kidney transplant recipients, who are HBsAg positive have a significantly increased mortality attributed to hepatic decompensation and complications,[n1-4] Prior to the discovery of effective antiretroviral, therapies such as lamivudine, hepatitis B virus q (HBV)...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics